When the $10K brand name drug is more af­ford­able than its $450 gener­ic: How PBMs con­trol the sys­tem

Phar­ma­cy ben­e­fit man­agers — the much-ma­ligned mid­dle­men be­tween drug man­u­fac­tur­ers and health in­sur­ers — of­ten tilt the mar­ket, 80% of which is con­trolled by 3 of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.